CombiMatrix Q4 Revenues Grow 25 Percent, Loss Widens

Feb 27, 2013

|

The story has been updated to include comments from the company's earnings conference call.

NEW YORK (GenomeWeb News) – CombiMatrix today said that revenues in the fourth quarter rose 25 percent year over year as revenues from core prenatal testing markets spiked 161 percent.

For the three months ended December 31, 2012, the Irvine, Calif.-based firm saw revenues increase to $1.5 million from $1.2 million a year ago.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

The Same Genes Keep Getting Asked to Prom

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

Keep Them in the Know

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

From Tusk to Cartel

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

This Week in Nature

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Featured White Papers

FFPE controls for use with Ion AmpliSeq and Oncomine ALK, RET, and ROS1 fusion assays

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Oct

17

Featured Webinar

Reliable RNA-Seq Expression Profiling from Low-Quality FFPE Biobank Samples

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct

25

Featured Webinar

A Comprehensive Strategy for Evaluating NGS Liquid Biopsy and Tumor Tissue Assays

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate NGS oncology assays for genomic tumor profiling of plasma and tissue samples.

Main menu